Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody

被引：2
|
作者：
Regidor, Bernard Sean [1 ]
Siddiqi, Dilawer [1 ]
Beatty, Bethany Marie [1 ]
Goldwater, Marissa-Skye [2 ]
Jew, Scott [1 ,2 ]
Bujarski, Sean [1 ,2 ]
Swift, Regina [1 ]
Kim, Susanna
Berenson, James R. R. [1 ,2 ,3 ,4 ]
机构：
[1] Berenson Canc Ctr, West Hollywood, CA USA
[2] Inst Myeloma & Bone Canc Res, West Hollywood, CA USA
[3] Oncotherapeut, West Hollywood, CA USA
[4] Inst Myeloma & Bone Canc Res, 9201 W Sunset Blvd,Ste 300, West Hollywood, CA 90069 USA
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2023年 / 110卷 / 02期
关键词：
anti-CD38; daratumumab; multiple myeloma; venetoclax;
D O I：
10.1111/ejh.13896
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：222 / 223
页数：2
相关论文
共 37 条
  • [31] Antibody Response to Breakthrough SARS-CoV-2 Infection in "Booster" Vaccinated Patients with Multiple Myeloma According to B/T/NK Lymphocyte Absolute Counts and anti-CD38 Treatments
    Sgherza, Nicola
    Mestice, Anna
    Larocca, Angela Maria Vittoria
    Musto, Pellegrino
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2024, 16 (01)
  • [32] A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma
    Chakraborty, Rajshekhar
    Yan, Ying
    Royal, Mike
    BLOOD, 2021, 138
  • [33] MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
    Kumar, Shaji K.
    Garfall, Alfred L.
    Trudel, Suzanne
    Ocio, Enrique M.
    Scott, Emma
    Huang, Lin
    Ma, Xuewen
    Olyslager, Yunsi
    Thakkar, Payal
    Pei, Lixia
    Heuck, Christoph
    Terpos, Evangelos
    BLOOD, 2022, 140 : 7292 - 7293
  • [34] Monumental-6: A Phase 3 Study of Talquetamab plus Pomalidomide or Talquetamab plus Teclistamab Vs Elotuzumab plus Pomalidomide plus Dexamethasone (EPd) or Pomalidomide plus Bortezomib plus Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody
    Nooka, Ajay K.
    Mian, Hira
    Lee, Cindy
    Rodriguez-Otero, Paula
    Kumar, Shaji
    Einsele, Hermann
    Vishwamitra, Deeksha
    Vieyra, Diego
    Kane, Colleen
    Kosh, Michele
    Masterson, Tara J.
    Heuck, Christoph
    Kansagra, Ankit
    Moreau, Philippe
    BLOOD, 2024, 144 : 47571 - 47572
  • [35] Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study
    Offidani, Massimo
    Cavo, Michele
    Derudas, Daniele
    Di Raimondo, Francesco
    Cuneo, Antonio
    Baldini, Luca
    Della Pepa, Roberta
    Musso, Maurizio
    Boccadoro, Mario
    Musto, Pellegrino
    Petrucci, Maria Teresa
    Belotti, Angelo
    BLOOD, 2022, 140 : 7222 - 7223
  • [36] Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
    Mateos, Maria-Victoria
    Weisel, Katja
    Martin, Thomas
    Berdeja, Jesus G.
    Jakubowiak, Andrzej
    Stewart, A. Keith
    Jagannath, Sundar
    Lin, Yi
    Diels, Joris
    Ghilotti, Francesca
    Thilakarathne, Pushpike
    Perualila, Nolen J.
    Cabrieto, Jedelyn
    Haefliger, Benjamin
    Erler-Yates, Nichola
    Hague, Clare
    Jackson, Carolyn C.
    Schecter, Jordan M.
    Strulev, Vadim
    Nesheiwat, Tonia
    Pacaud, Lida
    Einsele, Hermann
    Moreau, Philippe
    HAEMATOLOGICA, 2023, 108 (08) : 2192 - 2204
  • [37] The Locommotion Study (MMY4001): A Prospective, Multinational Study of RealLife Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression
    Delforge, Michel
    Moreau, Philippe
    Mateos, Maria-Victoria
    De Stefano, Valerio
    Weisel, Katja
    San-Miguel, Jesus
    Einsele, Hermann
    Facon, Thierry
    Boccadoro, Mario
    Goldschmidt, Hartmut
    Cavo, Michele
    Rosinol, Laura
    Kaiser, Martin F.
    Gay, Francesca
    Scheid, Christof
    Broyl, Annemiek
    Van De Donk, Niels W. C. J.
    Rodriguez, Paula
    Potamianou, Anna
    Sakabedoyan, Caline
    Strulev, Vadim
    Nesheiwat, Tonia
    Bergmans, Paul
    Rizvi, Syed
    Pilatowicz, Arkadiusz
    Sonneveld, Pieter
    BLOOD, 2019, 134
1234